Selected research
Industry Research
Botanical and Herbal Drug Industry Research Report 2026
Market perspective
The global Botanical and Herbal Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Botanical and Herbal Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Botanical and Herbal Drug market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Botanical and Herbal Drug market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Botanical and Herbal Drug include China TCM, Yunnan Baiyao, Tong Ren Tang, Kwangdong, Guangzhou Baiyunshan Pharmaceutical, Weleda, Tsumura, Tasly Holding Group and Taiji, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Botanical and Herbal Drug market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Botanical and Herbal Drug.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Botanical and Herbal Drug Market by Company
China TCM
Yunnan Baiyao
Tong Ren Tang
Kwangdong
Guangzhou Baiyunshan Pharmaceutical
Weleda
Tsumura
Tasly Holding Group
Taiji
Schwabe
Jumpcan Pharmaceutical
Huarun 999
GW Pharmaceuticals
Buchang Pharmaceuticals
Bionorica Se
Botanical and Herbal Drug Segment by Type
Prescription Drug
OTC
Botanical and Herbal Drug Segment by Application
Respiratory System
Cardiovascular
Tumor
Other
Botanical and Herbal Drug Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Botanical and Herbal Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Botanical and Herbal Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Botanical and Herbal Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Botanical and Herbal Drug companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Prescription Drug
- OTC
Applications
- Respiratory System
- Cardiovascular
- Tumor
- Other
Companies covered
- China TCM
- Yunnan Baiyao
- Tong Ren Tang
- Kwangdong
- Guangzhou Baiyunshan Pharmaceutical
- Weleda
- Tsumura
- Tasly Holding Group
- Taiji
- Schwabe
- Jumpcan Pharmaceutical
- Huarun 999
- GW Pharmaceuticals
- Buchang Pharmaceuticals
- Bionorica Se
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Botanical and Herbal Drug by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Prescription Drug
- 2.2.3 OTC
- 2.3 Botanical and Herbal Drug by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Respiratory System
- 2.3.3 Cardiovascular
- 2.3.4 Tumor
- 2.3.5 Other
- 2.4 Assumptions and Limitations
3 Botanical and Herbal Drug Breakdown Data by Type
- 3.1 Global Botanical and Herbal Drug Historic Market Size by Type (2021-2026)
- 3.2 Global Botanical and Herbal Drug Forecasted Market Size by Type (2027-2032)
4 Botanical and Herbal Drug Breakdown Data by Application
- 4.1 Global Botanical and Herbal Drug Historic Market Size by Application (2021-2026)
- 4.2 Global Botanical and Herbal Drug Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Botanical and Herbal Drug Market Perspective (2021-2032)
- 5.2 Global Botanical and Herbal Drug Growth Trends by Region
- 5.2.1 Global Botanical and Herbal Drug Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Botanical and Herbal Drug Historic Market Size by Region (2021-2026)
- 5.2.3 Botanical and Herbal Drug Forecasted Market Size by Region (2027-2032)
- 5.3 Botanical and Herbal Drug Market Dynamics
- 5.3.1 Botanical and Herbal Drug Industry Trends
- 5.3.2 Botanical and Herbal Drug Market Drivers
- 5.3.3 Botanical and Herbal Drug Market Challenges
- 5.3.4 Botanical and Herbal Drug Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Botanical and Herbal Drug Players by Revenue
- 6.1.1 Global Top Botanical and Herbal Drug Players by Revenue (2021-2026)
- 6.1.2 Global Botanical and Herbal Drug Revenue Market Share by Players (2021-2026)
- 6.2 Global Botanical and Herbal Drug Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Botanical and Herbal Drug Head Office and Area Served
- 6.4 Global Botanical and Herbal Drug Players, Product Type & Application
- 6.5 Global Botanical and Herbal Drug Manufacturers Established Date
- 6.6 Global Botanical and Herbal Drug Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Botanical and Herbal Drug Market Size (2021-2032)
- 7.2 North America Botanical and Herbal Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Botanical and Herbal Drug Market Size by Country (2021-2026)
- 7.4 North America Botanical and Herbal Drug Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Botanical and Herbal Drug Market Size (2021-2032)
- 8.2 Europe Botanical and Herbal Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Botanical and Herbal Drug Market Size by Country (2021-2026)
- 8.4 Europe Botanical and Herbal Drug Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Botanical and Herbal Drug Market Size (2021-2032)
- 9.2 Asia-Pacific Botanical and Herbal Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Botanical and Herbal Drug Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Botanical and Herbal Drug Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Botanical and Herbal Drug Market Size (2021-2032)
- 10.2 South America Botanical and Herbal Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Botanical and Herbal Drug Market Size by Country (2021-2026)
- 10.4 South America Botanical and Herbal Drug Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Botanical and Herbal Drug Market Size (2021-2032)
- 11.2 Middle East & Africa Botanical and Herbal Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Botanical and Herbal Drug Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Botanical and Herbal Drug Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 China TCM
- 12.1.1 China TCM Company Information
- 12.1.2 China TCM Business Overview
- 12.1.3 China TCM Revenue in Botanical and Herbal Drug Business (2021-2026)
- 12.1.4 China TCM Botanical and Herbal Drug Product Portfolio
- 12.1.5 China TCM Recent Developments
- 12.2 Yunnan Baiyao
- 12.2.1 Yunnan Baiyao Company Information
- 12.2.2 Yunnan Baiyao Business Overview
- 12.2.3 Yunnan Baiyao Revenue in Botanical and Herbal Drug Business (2021-2026)
- 12.2.4 Yunnan Baiyao Botanical and Herbal Drug Product Portfolio
- 12.2.5 Yunnan Baiyao Recent Developments
- 12.3 Tong Ren Tang
- 12.3.1 Tong Ren Tang Company Information
- 12.3.2 Tong Ren Tang Business Overview
- 12.3.3 Tong Ren Tang Revenue in Botanical and Herbal Drug Business (2021-2026)
- 12.3.4 Tong Ren Tang Botanical and Herbal Drug Product Portfolio
- 12.3.5 Tong Ren Tang Recent Developments
- 12.4 Kwangdong
- 12.4.1 Kwangdong Company Information
- 12.4.2 Kwangdong Business Overview
- 12.4.3 Kwangdong Revenue in Botanical and Herbal Drug Business (2021-2026)
- 12.4.4 Kwangdong Botanical and Herbal Drug Product Portfolio
- 12.4.5 Kwangdong Recent Developments
- 12.5 Guangzhou Baiyunshan Pharmaceutical
- 12.5.1 Guangzhou Baiyunshan Pharmaceutical Company Information
- 12.5.2 Guangzhou Baiyunshan Pharmaceutical Business Overview
- 12.5.3 Guangzhou Baiyunshan Pharmaceutical Revenue in Botanical and Herbal Drug Business (2021-2026)
- 12.5.4 Guangzhou Baiyunshan Pharmaceutical Botanical and Herbal Drug Product Portfolio
- 12.5.5 Guangzhou Baiyunshan Pharmaceutical Recent Developments
- 12.6 Weleda
- 12.6.1 Weleda Company Information
- 12.6.2 Weleda Business Overview
- 12.6.3 Weleda Revenue in Botanical and Herbal Drug Business (2021-2026)
- 12.6.4 Weleda Botanical and Herbal Drug Product Portfolio
- 12.6.5 Weleda Recent Developments
- 12.7 Tsumura
- 12.7.1 Tsumura Company Information
- 12.7.2 Tsumura Business Overview
- 12.7.3 Tsumura Revenue in Botanical and Herbal Drug Business (2021-2026)
- 12.7.4 Tsumura Botanical and Herbal Drug Product Portfolio
- 12.7.5 Tsumura Recent Developments
- 12.8 Tasly Holding Group
- 12.8.1 Tasly Holding Group Company Information
- 12.8.2 Tasly Holding Group Business Overview
- 12.8.3 Tasly Holding Group Revenue in Botanical and Herbal Drug Business (2021-2026)
- 12.8.4 Tasly Holding Group Botanical and Herbal Drug Product Portfolio
- 12.8.5 Tasly Holding Group Recent Developments
- 12.9 Taiji
- 12.9.1 Taiji Company Information
- 12.9.2 Taiji Business Overview
- 12.9.3 Taiji Revenue in Botanical and Herbal Drug Business (2021-2026)
- 12.9.4 Taiji Botanical and Herbal Drug Product Portfolio
- 12.9.5 Taiji Recent Developments
- 12.10 Schwabe
- 12.10.1 Schwabe Company Information
- 12.10.2 Schwabe Business Overview
- 12.10.3 Schwabe Revenue in Botanical and Herbal Drug Business (2021-2026)
- 12.10.4 Schwabe Botanical and Herbal Drug Product Portfolio
- 12.10.5 Schwabe Recent Developments
- 12.11 Jumpcan Pharmaceutical
- 12.11.1 Jumpcan Pharmaceutical Company Information
- 12.11.2 Jumpcan Pharmaceutical Business Overview
- 12.11.3 Jumpcan Pharmaceutical Revenue in Botanical and Herbal Drug Business (2021-2026)
- 12.11.4 Jumpcan Pharmaceutical Botanical and Herbal Drug Product Portfolio
- 12.11.5 Jumpcan Pharmaceutical Recent Developments
- 12.12 Huarun 999
- 12.12.1 Huarun 999 Company Information
- 12.12.2 Huarun 999 Business Overview
- 12.12.3 Huarun 999 Revenue in Botanical and Herbal Drug Business (2021-2026)
- 12.12.4 Huarun 999 Botanical and Herbal Drug Product Portfolio
- 12.12.5 Huarun 999 Recent Developments
- 12.13 GW Pharmaceuticals
- 12.13.1 GW Pharmaceuticals Company Information
- 12.13.2 GW Pharmaceuticals Business Overview
- 12.13.3 GW Pharmaceuticals Revenue in Botanical and Herbal Drug Business (2021-2026)
- 12.13.4 GW Pharmaceuticals Botanical and Herbal Drug Product Portfolio
- 12.13.5 GW Pharmaceuticals Recent Developments
- 12.14 Buchang Pharmaceuticals
- 12.14.1 Buchang Pharmaceuticals Company Information
- 12.14.2 Buchang Pharmaceuticals Business Overview
- 12.14.3 Buchang Pharmaceuticals Revenue in Botanical and Herbal Drug Business (2021-2026)
- 12.14.4 Buchang Pharmaceuticals Botanical and Herbal Drug Product Portfolio
- 12.14.5 Buchang Pharmaceuticals Recent Developments
- 12.15 Bionorica Se
- 12.15.1 Bionorica Se Company Information
- 12.15.2 Bionorica Se Business Overview
- 12.15.3 Bionorica Se Revenue in Botanical and Herbal Drug Business (2021-2026)
- 12.15.4 Bionorica Se Botanical and Herbal Drug Product Portfolio
- 12.15.5 Bionorica Se Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst